Keros Therapeutics (NASDAQ:KROS) Shares Down 5.7% Following Analyst Downgrade

Keros Therapeutics, Inc. (NASDAQ:KROS)’s stock price was down 5.7% on Tuesday after Oppenheimer lowered their price target on the stock from $102.00 to $63.00. Oppenheimer currently has an outperform rating on the stock. Keros Therapeutics traded as low as $18.12 and last traded at $18.32. Approximately 350,670 shares were traded during mid-day trading, a decline of 24% from the average daily volume of 463,453 shares. The stock had previously closed at $19.42.

A number of other research firms have also weighed in on KROS. Guggenheim lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Wedbush restated an “outperform” rating and set a $84.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. Bank of America lowered their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Finally, Jefferies Financial Group began coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating for the company. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $81.33.

Institutional Trading of Keros Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. grew its position in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after purchasing an additional 577,220 shares during the period. Alkeon Capital Management LLC lifted its holdings in Keros Therapeutics by 18.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after purchasing an additional 298,694 shares in the last quarter. Parkman Healthcare Partners LLC grew its holdings in shares of Keros Therapeutics by 112.3% during the third quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company’s stock worth $24,493,000 after buying an additional 223,155 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of Keros Therapeutics by 814.6% in the third quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock valued at $12,990,000 after buying an additional 199,245 shares during the last quarter. Finally, FMR LLC raised its position in shares of Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after buying an additional 179,374 shares during the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Price Performance

The stock has a market capitalization of $693.88 million, a PE ratio of -3.29 and a beta of 1.20. The company’s 50 day moving average price is $56.64 and its two-hundred day moving average price is $52.06.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Keros Therapeutics’s quarterly revenue was up 4750.0% on a year-over-year basis. During the same quarter last year, the business earned ($1.33) earnings per share. Analysts forecast that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.